Skip to content

Clinical trials

Completed Recurrence trials with no applicable phase

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Recurrence Phase: Not applicable Status: Completed Clear all

223 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20002
20015
20022
20037
20046
20053
20066
20073
20089
200910
201012
20117
20126
201311
201413
201516
20167
201713
201811
201915
202011
202110
202210
202310
20247
20261

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed223

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Assistance Publique - Hôpitaux de Paris6
Mansoura University5
M.D. Anderson Cancer Center4
Massachusetts General Hospital4
Roswell Park Cancer Institute4
Fred Hutchinson Cancer Center3
Helsinki University Central Hospital3
Insel Gruppe AG, University Hospital Bern3
Nanchong Central Hospital3
University of Pittsburgh3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Recurrence223
Neoplasms16
Precursor Cell Lymphoblastic Leukemia-Lymphoma16
Leukemia, Myeloid, Acute14
Burkitt Lymphoma13
Dendritic Cell Sarcoma, Interdigitating13
Hodgkin Disease13
Leukemia, Lymphocytic, Chronic, B-Cell13
Lymphoma, Follicular13
Major Depressive Disorder13

Trials

Showing 1 to 25 of 223. Each trial links to its page on Pharma Observatory.

123 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.